Victoria Garfinkel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victoria Garfinkel has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Heather Woodworth Goff
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
3 shared publications - Beth A. Childs
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas
2 shared publications Brielle E Johnson
Department of Dermatology, University of Texas Southwestern Medical Center , Dallas, TX
2 shared publications- Kiran A. Kumar
Department of Radiation Oncology, University of Texas Southwestern Medical Center , Dallas, TX
2 shared publications - Praveen Ramakrishnan Geethakumari
Division of Hematology and Oncology, Department of Medicine, University of Texas Southwestern Medical Center , Dallas, TX
2 shared publications - Todd Anthony Aguilera
The University of Texas Southwestern Medical Center
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (6) , 1096-1098
Reply to ‘Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides’
Authors’ response to ‘Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides’, by Oleg Akilov.
- 18 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (6) , 1096-1098
Open AccessReply to ‘Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides’
Authors’ response to ‘Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides’, by Oleg Akilov.
- Open Access
- 9 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1167-1170
Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: a retrospective cohort study
Dear Editor, Cutaneous T-cell lymphomas (CTCLs) are rare non-Hodgkin lymphomas, affecting 8.8 per 1 000 000 people annually.1 Bexarotene is the only retinoid approved by the US Food and Drug Administration for mycosis fungoides (MF),2 the most common CTCL subtype, but its use is limited by high cost and adverse effects, particularly thyroid and lipid abnormalities.3 Acitretin, a less expensive second-generation retinoid used in psoriasis, is prescribed off-label in MF, yet supporting data remain limited to small retrospective case series.4 However, our clinical experience suggests dose-dependent efficacy with acitretin, supporting formal evaluation of its dose–response pattern in MF.
- 9 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1167-1170
Open AccessDose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: a retrospective cohort study
Dear Editor, Cutaneous T-cell lymphomas (CTCLs) are rare non-Hodgkin lymphomas, affecting 8.8 per 1 000 000 people annually.1 Bexarotene is the only retinoid approved by the US Food and Drug Administration for mycosis fungoides (MF),2 the most common CTCL subtype, but its use is limited by high cost and adverse effects, particularly thyroid and lipid abnormalities.3 Acitretin, a less expensive second-generation retinoid used in psoriasis, is prescribed off-label in MF, yet supporting data remain limited to small retrospective case series.4 However, our clinical experience suggests dose-dependent efficacy with acitretin, supporting formal evaluation of its dose–response pattern in MF.
- Open Access
- 16 November 2024
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 40 (6) , e13009
A Retrospective Comparison Between Home and in‐Office NB‐UVB Efficacy for Patients With Mycosis Fungoides
Introduction: This study addresses the gap in research comparing the effectiveness between home and in‐office narrowband ultraviolet B (NB‐UVB) phototherapy for the treatment of mycosis fungoides (MF). Elderly and disabled patients with this condition disproportionally lack access to home units due to insurance denial.Materials and Methods: A retrospective review included patients diagnosed with MF or Sezary syndrome who underwent either in‐office or home UVB between 2016 and 2023. Eighty‐four patients used home NB‐UVB, while 75 used in‐office. Clinical characteristics, treatment response, and access were evaluated.Results: Overall, there was no significant difference in response rates between home and in‐office NB‐UVB phototherapy. Subgroup analysis based on adjuvant treatment revealed a significant difference in clinical response rates for patients using NB‐UVB with topicals (p = 0.008) and NB‐UVB with multiple systemic therapies (p = 0.04). Financial and time constraints were the most common cause of treatment discontinuation for in‐office patients (28%).Conclusions: The effectiveness of home NB‐UVB treatment is comparable, if not superior, to in‐office treatment, likely attributed to treatment ease in access and compliance. Medicare and other health insurance companies should expand coverage to include home‐based phototherapy for patients with MF, a potentially fatal cancer with a relative paucity of effective alternate therapies.
- 16 November 2024
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 40 (6) , e13009
Open AccessA Retrospective Comparison Between Home and in‐Office NB‐UVB Efficacy for Patients With Mycosis Fungoides
Introduction: This study addresses the gap in research comparing the effectiveness between home and in‐office narrowband ultraviolet B (NB‐UVB) phototherapy for the treatment of mycosis fungoides (MF). Elderly and disabled patients with this condition disproportionally lack access to home units due to insurance denial.Materials and Methods: A retrospective review included patients diagnosed with MF or Sezary syndrome who underwent either in‐office or home UVB between 2016 and 2023. Eighty‐four patients used home NB‐UVB, while 75 used in‐office. Clinical characteristics, treatment response, and access were evaluated.Results: Overall, there was no significant difference in response rates between home and in‐office NB‐UVB phototherapy. Subgroup analysis based on adjuvant treatment revealed a significant difference in clinical response rates for patients using NB‐UVB with topicals (p = 0.008) and NB‐UVB with multiple systemic therapies (p = 0.04). Financial and time constraints were the most common cause of treatment discontinuation for in‐office patients (28%).Conclusions: The effectiveness of home NB‐UVB treatment is comparable, if not superior, to in‐office treatment, likely attributed to treatment ease in access and compliance. Medicare and other health insurance companies should expand coverage to include home‐based phototherapy for patients with MF, a potentially fatal cancer with a relative paucity of effective alternate therapies.
- Open Access
- 5 November 2024
- Published by Wiley
Drug-induced mimics of Mycosis Fungoides: Two case reports and a systemic literature review
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, often posing diagnostic challenges due to its resemblance to benign dermatoses, particularly drug-induced eruptions. Aims: This study aims to examine cases where drug-induced eruptions mimic MF and provide insights to improve diagnostic approaches. Methods and Results : A literature review following PRISMA guidelines was conducted using PubMed, Embase, and Scopus databases, focusing on case reports and series published after 1990 involving histologic mimics of MF. Data on demographics, clinical presentation, implicated drugs, histologic findings, and treatment outcomes were analyzed. From 46 articles rendered, a total of 25 were included in our study that yielded forty cases to analyze. The average age of patients was 56 years and 58% were males. Anticonvulsants were the most frequently implicated drugs (58%), followed by anti-arrhythmic medications (10%) and immunomodulators (8%). Other category medications made up 25% of reported cases. Clinical presentations varied, with hypersensitivity-like reactions being common in patients on anticonvulsants (59%) and immunomodulators (67%), while MF-like lesions were more frequent in other category medications (56%). Histologically, atypical lymphocytes and epidermotropism were common findings, particularly in patients on anticonvulsants. Immunohistochemical analysis revealed significant difference in CD markers and drug class ( P = 0.04). Discontinuation of the offending drug often led to clinical remission, with an average resolution time of 61 days. Conclusion : Diagnosing MF requires careful consideration of the full clinicopathologic picture, especially when drug-induced mimics are suspected. Histologic and immunohistochemical evaluations, such as positivity for both CD4 and CD8 T-cells in the lymphocytic infiltrate, can be giveaways to a drug-induced etiology. Repeat biopsies after drug cessation can be particularly valuable in distinguishing true MF from drug-induced pseudo-lymphomas. These findings highlight the importance of considering drug-induced etiologies in MF-like presentations to avoid unnecessary treatments and ensure appropriate patient management.
- 5 November 2024
- Published by Wiley
Open AccessDrug-induced mimics of Mycosis Fungoides: Two case reports and a systemic literature review
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, often posing diagnostic challenges due to its resemblance to benign dermatoses, particularly drug-induced eruptions. Aims: This study aims to examine cases where drug-induced eruptions mimic MF and provide insights to improve diagnostic approaches. Methods and Results : A literature review following PRISMA guidelines was conducted using PubMed, Embase, and Scopus databases, focusing on case reports and series published after 1990 involving histologic mimics of MF. Data on demographics, clinical presentation, implicated drugs, histologic findings, and treatment outcomes were analyzed. From 46 articles rendered, a total of 25 were included in our study that yielded forty cases to analyze. The average age of patients was 56 years and 58% were males. Anticonvulsants were the most frequently implicated drugs (58%), followed by anti-arrhythmic medications (10%) and immunomodulators (8%). Other category medications made up 25% of reported cases. Clinical presentations varied, with hypersensitivity-like reactions being common in patients on anticonvulsants (59%) and immunomodulators (67%), while MF-like lesions were more frequent in other category medications (56%). Histologically, atypical lymphocytes and epidermotropism were common findings, particularly in patients on anticonvulsants. Immunohistochemical analysis revealed significant difference in CD markers and drug class ( P = 0.04). Discontinuation of the offending drug often led to clinical remission, with an average resolution time of 61 days. Conclusion : Diagnosing MF requires careful consideration of the full clinicopathologic picture, especially when drug-induced mimics are suspected. Histologic and immunohistochemical evaluations, such as positivity for both CD4 and CD8 T-cells in the lymphocytic infiltrate, can be giveaways to a drug-induced etiology. Repeat biopsies after drug cessation can be particularly valuable in distinguishing true MF from drug-induced pseudo-lymphomas. These findings highlight the importance of considering drug-induced etiologies in MF-like presentations to avoid unnecessary treatments and ensure appropriate patient management.